Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

Bicycle Therapeutics Limited

Bicycle Therapeutics Limited

BCYC

0.00

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ: BCYC) with a Buy and lowers the price target from $15 to $14.